Effects of Sclareol Against Small Cell Lung Carcinoma and the Related Mechanism:
Animals
Antineoplastic Agents, Phytogenic
/ pharmacology
Apoptosis
/ drug effects
Cell Cycle
/ drug effects
Cell Line, Tumor
Cell Survival
/ drug effects
DNA Damage
Diterpenes
/ pharmacology
Female
Humans
Lung Neoplasms
/ drug therapy
Mice
Mice, Inbred BALB C
Mice, Nude
Signal Transduction
/ drug effects
Small Cell Lung Carcinoma
/ drug therapy
Treatment Outcome
Xenograft Model Antitumor Assays
DNA damage
Sclareol
Small cell lung carcinoma
apoptosis
cell cycle
xenograft
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
10
06
2020
revised:
06
07
2020
accepted:
08
07
2020
entrez:
4
9
2020
pubmed:
4
9
2020
medline:
22
9
2020
Statut:
ppublish
Résumé
This study aimed to investigate the anticancer effects and potential mechanisms of sclareol in a human small cell lung carcinoma (SCLC) cell line. Cell viability was determined by the MTT assay. Cell cycle, apoptosis and caspase activity were evaluated by flow cytometry. Cell cycle and DNA damage related protein expression was determined by western blotting. In vivo evaluation of sclareol was carried out in xenografted tumor mice models. Sclareol significantly reduced cell viability, induced G Sclareol might be a novel and effective therapeutic agent for the treatment of SCLC patients.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
This study aimed to investigate the anticancer effects and potential mechanisms of sclareol in a human small cell lung carcinoma (SCLC) cell line.
MATERIALS AND METHODS
METHODS
Cell viability was determined by the MTT assay. Cell cycle, apoptosis and caspase activity were evaluated by flow cytometry. Cell cycle and DNA damage related protein expression was determined by western blotting. In vivo evaluation of sclareol was carried out in xenografted tumor mice models.
RESULTS
RESULTS
Sclareol significantly reduced cell viability, induced G
CONCLUSION
CONCLUSIONS
Sclareol might be a novel and effective therapeutic agent for the treatment of SCLC patients.
Identifiants
pubmed: 32878783
pii: 40/9/4947
doi: 10.21873/anticanres.14498
doi:
Substances chimiques
Antineoplastic Agents, Phytogenic
0
Diterpenes
0
sclareol
B607NP0Q8Y
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4947-4960Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.